Diamonds and Dogs


Biogen (BIIB) soars 25% on positive clinical trials for their Alzheimer drug. Biogen's stock dropped 29% back in March on a smaller clinical trail that didn't show positive results for the same drug. However, the new analysis of a larger data set showed that aducanumab actually did work, reducing clinical decline in patients with early-stage Alzheimer's disease. Biogen will now submit their Alzheimer's drug for FDA approval as early as next year. If approved, it would be the first drug approved to reduce the clinical decline of Alzheimer's disease. Biogen also released better than expected earnings results.

McDonald's (MCD) taking a hit. The fast-food giant is down 3% to a five-month low on downbeat third-quarter earnings. McDonald's actually missed on earnings and sales. Global sales did beat expectations, but softness in the U.S. market could spark worries that the sector is becoming more competitive. On the plus side, McDonald's did hike their dividend 7.7% boosting the dividend yield to 2.4%.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.